About Vivimed Labs (Alathur) Private Limited
Data last updated: 24 July 2025
Vivimed Labs (Alathur) Private Limited was a private limited company based in Mumbai, Maharashtra, India, operated as a subsidiary of Vivimed Labs Limited. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It specialised in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 23 November 2006.
Registered with ROC Mumbai under CIN U24219MH2006PTC165760.
Capital: an authorised share capital of ₹70 Cr and a paid-up capital of ₹50.17 Cr. It was led by directors including Sandeep Varalwar and Santosh Varalwar.
Last AGM: 26 September 2015. Financial statements filed for year ended 31 March 2016. Office: 130 Shanta Industrial Estate 1St Floor I.B.Patel Road Goregaon East, Mumbai, Maharashtra, India – 400063.
As per the financials filed for FY 2016, the company reported a revenue of ₹36.32 Cr, a growth of 29% compared to the previous year.
It operated as a subsidiary of Vivimed Labs Limited.
As per MCA filings, the company had satisfied charges of ₹53.5 Cr on record.
The company has been merged (amalgamated) with another entity and no longer exists separately. Business activities, if any, continue under the successor entity. The last known website on record is vivimedlabs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address130 Shanta Industrial Estate 1St Floor I.B.Patel Road Goregaon East, Mumbai, Maharashtra, India – 400063
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Vivimed Labs (Alathur) Private Limited
Vivimed Labs (Alathur) Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Vivimed Labs (Alathur) Private Limited
Vivimed Labs (Alathur) Private Limited is audited by SVRL and CO (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2025, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| SVRL and CO (ICAI peer reviewed, certificate valid till 2027-04-30) | FY 2025 | Statement on impact of audit qualification |
Board of Directors of Vivimed Labs (Alathur) Private Limited
Vivimed Labs (Alathur) Private Limited is currently managed by 3 directors, with 13 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Sandeep Varalwar
Also directs:
Vivimed Labs Limited, B B R Projects Private Limited
|
Director | 31 Jul 2013 | 12 Years 11 Months | As last reported |
|
Santosh Varalwar
Also directs:
Vivimed Labs Limited, B B R Projects Private Limited, Uquifa India Private Limited and 3 more
|
Director | 31 Jul 2013 | 12 Years 11 Months | As last reported |
| Manohar Rao Varalwar | Additional Director | 31 Jul 2013 | 12 Years 11 Months | As last reported |
Financials of Vivimed Labs (Alathur) Private Limited FY 2025 filings available
Vivimed Labs (Alathur) Private Limited reported revenue of ₹116.27 Cr (down 22% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹116.27 Cr | ₹149.07 Cr | ₹187.1 Cr | ₹237.29 Cr | ₹861.47 Cr | ₹1,058.8 Cr |
| Other Income | ₹4.37 Cr | ₹9.98 Cr | ₹96.8 Lakh | ₹1.27 Cr | ₹9.82 Cr | ₹8.26 Cr |
| Total Income | ₹120.64 Cr | ₹159.05 Cr | ₹188.07 Cr | ₹238.56 Cr | ₹871.29 Cr | ₹1,067.05 Cr |
| Cost of Materials Consumed | ₹57.76 Cr | ₹89.55 Cr | ₹109.95 Cr | ₹153 Cr | ₹356.56 Cr | ₹483.24 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹80.1 Lakh | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹2.09 Cr | -₹18.07 Cr | ₹160.76 Cr | ₹48.48 Lakh | -₹2.04 Cr | -₹20.69 Cr |
| Employee Benefit Expense | ₹28.39 Cr | ₹34.16 Cr | ₹32.67 Cr | ₹36.22 Cr | ₹195.66 Cr | ₹233.36 Cr |
| Finance Costs | ₹2.95 Cr | ₹2.43 Cr | ₹35.9 Cr | ₹39.76 Cr | ₹53.88 Cr | ₹58.89 Cr |
| Depreciation & Amortisation | - | ₹19.94 Cr | ₹108.41 Cr | ₹18.28 Cr | ₹55.49 Cr | ₹66.95 Cr |
| Other Expenses | ₹40.61 Cr | ₹76.87 Cr | ₹70.23 Cr | ₹55.64 Cr | ₹287.5 Cr | ₹354.78 Cr |
| Total Expenses | ₹152.03 Cr | ₹204.87 Cr | ₹518.72 Cr | ₹303.39 Cr | ₹947.06 Cr | ₹1,176.53 Cr |
| Profit Before Exceptional Items & Tax | - | -₹45.82 Cr | -₹330.65 Cr | -₹64.83 Cr | -₹75.77 Cr | -₹109.47 Cr |
| Exceptional Items | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹31.39 Cr | -₹45.82 Cr | -₹330.65 Cr | -₹64.83 Cr | -₹75.77 Cr | -₹109.47 Cr |
| Total Tax Expense | ₹11.3 Lakh | -₹37.7 Lakh | -₹2.12 Cr | ₹2.82 Cr | ₹2.03 Cr | -₹35.95 Lakh |
| Net Profit | -₹31.5 Cr | -₹45.45 Cr | -₹328.53 Cr | -₹67.65 Cr | -₹77.8 Cr | -₹109.12 Cr |
| attributable to Owners | - | ₹0 | -₹327.98 Cr | ₹0 | - | ₹0 |
| attributable to NCI | - | ₹0 | ₹0 | ₹0 | - | ₹0 |
| Other Comprehensive Income | - | ₹56.3 Lakh | ₹55.9 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | - | -₹44.88 Cr | -₹327.98 Cr | -₹67.65 Cr | -₹77.8 Cr | -₹109.12 Cr |
| EBITDA (computed) | - | -₹23.45 Cr | -₹186.34 Cr | -₹6.79 Cr | ₹33.61 Cr | ₹16.36 Cr |
| Basic EPS | - | ₹-5.48 | ₹-39.62 | ₹-8.16 | ₹-9.38 | ₹-13.16 |
| Diluted EPS | - | ₹-5.32 | ₹-38.46 | ₹-7.92 | ₹-9.11 | ₹-12.77 |
| Metrics | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total Assets | ₹920.83 Cr | ₹950.91 Cr | ₹988.35 Cr |
| Non-current Assets | ₹593.28 Cr | ₹608.33 Cr | ₹656.06 Cr |
| Current Assets | ₹327.56 Cr | ₹342.58 Cr | ₹332.29 Cr |
| Property, Plant & Equipment | ₹254.4 Cr | ₹262.86 Cr | ₹278.18 Cr |
| Inventories | ₹58.76 Cr | ₹64.06 Cr | ₹79.76 Cr |
| Trade Receivables | - | ₹82.82 Cr | ₹76.81 Cr |
| Cash & Equivalents | ₹70.8 Lakh | ₹2.03 Cr | ₹3.76 Cr |
| Equity (Net Worth) | - | -₹5.46 Cr | ₹39.42 Cr |
| Equity Share Capital | - | ₹16.58 Cr | ₹16.58 Cr |
| Borrowings (Non-current) | - | ₹63.57 Cr | ₹62.32 Cr |
| Borrowings (Current) | - | ₹313.36 Cr | ₹316.25 Cr |
| Total Debt (computed) | - | ₹376.93 Cr | ₹378.57 Cr |
| Current Liabilities | ₹408.2 Cr | ₹410.33 Cr | ₹424.3 Cr |
| Total Liabilities | - | ₹956.37 Cr | ₹948.92 Cr |
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -₹10.81 Cr | -₹23.99 Cr | ₹13.81 Cr | -₹658.47 Cr |
| Investing Cash Flow | ₹4.53 Cr | ₹28.29 Cr | -₹99 Lakh | ₹523.34 Cr |
| Financing Cash Flow | ₹4.96 Cr | -₹6.03 Cr | -₹16.24 Cr | -₹10.38 Cr |
| Capital Expenditure | -₹4.53 Cr | ₹0 | ₹99 Lakh | ₹0 |
| Free Cash Flow (computed) | -₹15.34 Cr | -₹23.99 Cr | ₹12.82 Cr | -₹658.47 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹1.32 Cr | -₹1.74 Cr | -₹3.42 Cr | -₹139.08 Cr |
| Metrics | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 | Q4 FY23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹15.99 Cr | ₹20.61 Cr | ₹21.39 Cr | ₹25.61 Cr | ₹36.51 Cr | ₹24.77 Cr | ₹29.37 Cr | ₹38.62 Cr | ₹41.46 Cr | ₹33.64 Cr | ₹35.35 Cr | ₹37.03 Cr |
| Other Income | ₹0 | ₹21.2 Lakh | ₹37.8 Lakh | ₹4.22 Cr | ₹6.7 Lakh | ₹2.7 Lakh | ₹6 Lakh | ₹7.62 Cr | ₹3.9 Lakh | ₹2.2 Cr | ₹11.2 Lakh | ₹68.3 Lakh |
| Total Income | ₹15.99 Cr | ₹20.82 Cr | ₹21.77 Cr | ₹29.83 Cr | ₹36.58 Cr | ₹24.8 Cr | ₹29.43 Cr | ₹46.24 Cr | ₹41.5 Cr | ₹35.84 Cr | ₹35.46 Cr | ₹37.71 Cr |
| Cost of Materials Consumed | ₹8.93 Cr | ₹5.3 Cr | ₹10.77 Cr | ₹7.76 Cr | ₹14.71 Cr | ₹15.47 Cr | ₹19.82 Cr | ₹33.89 Cr | ₹20.83 Cr | ₹17.36 Cr | ₹17.47 Cr | ₹22.71 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.41 Cr | ₹63 Lakh | ₹0 | ₹77.5 Lakh | ₹5.9 Lakh |
| Changes in Inventories | -₹1.03 Cr | ₹3.82 Cr | -₹97.5 Lakh | ₹3.69 Cr | ₹4.97 Cr | -₹4.11 Cr | -₹2.46 Cr | -₹18.6 Cr | ₹30.5 Lakh | ₹37.6 Lakh | -₹15.5 Lakh | ₹159.25 Cr |
| Employee Benefit Expense | ₹3.7 Cr | ₹5.6 Cr | ₹5.71 Cr | ₹8.79 Cr | ₹7.29 Cr | ₹6.29 Cr | ₹6.03 Cr | ₹6.99 Cr | ₹9.75 Cr | ₹9.78 Cr | ₹7.63 Cr | ₹8.82 Cr |
| Finance Costs | ₹1 Cr | ₹1.66 Cr | ₹57.6 Lakh | ₹1.74 Cr | ₹48.3 Lakh | ₹42.7 Lakh | ₹29.7 Lakh | -₹33.33 Cr | ₹13.21 Cr | ₹11.89 Cr | ₹10.66 Cr | ₹8.52 Cr |
| Depreciation & Amortisation | ₹4.63 Cr | ₹4.9 Cr | ₹5.01 Cr | - | ₹6.62 Cr | ₹4.1 Cr | ₹4.01 Cr | ₹5.83 Cr | ₹4.7 Cr | ₹4.7 Cr | ₹4.7 Cr | ₹95.92 Cr |
| Other Expenses | ₹15.32 Cr | ₹6.85 Cr | ₹6.17 Cr | ₹7.38 Cr | ₹8.47 Cr | ₹7.76 Cr | ₹9.93 Cr | ₹46.21 Cr | ₹8.67 Cr | ₹12.02 Cr | ₹9.97 Cr | ₹10.49 Cr |
| Total Expenses | ₹32.54 Cr | ₹28.13 Cr | ₹27.26 Cr | ₹34.84 Cr | ₹42.55 Cr | ₹29.94 Cr | ₹37.62 Cr | ₹39.59 Cr | ₹58.1 Cr | ₹56.14 Cr | ₹51.04 Cr | ₹305.77 Cr |
| Profit Before Exceptional Items & Tax | -₹16.55 Cr | -₹7.3 Cr | -₹5.49 Cr | - | -₹5.98 Cr | -₹5.14 Cr | -₹8.19 Cr | ₹6.65 Cr | -₹16.6 Cr | -₹20.3 Cr | -₹15.58 Cr | -₹268.05 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹16.55 Cr | -₹7.3 Cr | -₹5.49 Cr | -₹5.01 Cr | -₹5.98 Cr | -₹5.14 Cr | -₹8.19 Cr | ₹6.65 Cr | -₹16.6 Cr | -₹20.3 Cr | -₹15.58 Cr | -₹268.05 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹11.3 Lakh | ₹0 | ₹0 | ₹0 | ₹1.39 Cr | -₹55.4 Lakh | ₹0 | ₹0 | -₹2.07 Cr |
| Net Profit | -₹16.55 Cr | -₹7.3 Cr | -₹5.49 Cr | -₹5.13 Cr | -₹5.98 Cr | -₹5.14 Cr | -₹8.19 Cr | ₹5.26 Cr | -₹16.05 Cr | -₹20.3 Cr | -₹15.58 Cr | -₹265.99 Cr |
| attributable to Owners | - | ₹0 | ₹0 | - | ₹0 | - | ₹0 | ₹0 | - | ₹0 | ₹0 | -₹265.43 Cr |
| attributable to NCI | - | ₹0 | ₹0 | - | ₹0 | - | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹56.3 Lakh | ₹0 | ₹0 | ₹0 | ₹55.9 Lakh |
| Total Comprehensive Income | -₹16.55 Cr | -₹7.3 Cr | -₹5.49 Cr | - | -₹5.98 Cr | -₹5.14 Cr | -₹8.19 Cr | ₹5.83 Cr | -₹16.05 Cr | -₹20.3 Cr | -₹15.58 Cr | -₹265.43 Cr |
| EBITDA (computed) | -₹10.92 Cr | -₹74.3 Lakh | ₹9.6 Lakh | - | ₹1.12 Cr | -₹61.4 Lakh | -₹3.88 Cr | -₹20.85 Cr | ₹1.31 Cr | -₹3.7 Cr | -₹21.5 Lakh | -₹163.61 Cr |
| Basic EPS | ₹-0.88 | ₹-0.88 | ₹-0.66 | - | ₹-0.72 | ₹-0.60 | ₹-0.99 | ₹0.64 | ₹-1.24 | ₹-2.45 | ₹1.88 | ₹-32.08 |
| Diluted EPS | ₹-0.85 | ₹-0.85 | ₹-0.64 | - | ₹-0.70 | ₹-0.58 | ₹-0.96 | ₹0.62 | ₹-1.20 | ₹-2.38 | ₹1.82 | ₹-31.14 |
| Segment · FY 2024 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharma Business | ₹143.17 Cr | -₹27.33 Cr | - | - |
| Speciality Chemicals Business | ₹5.9 Cr | -₹26.03 Cr | - | - |
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹103.6 Cr | ₹136.8 Cr | ₹176.83 Cr | ₹218.37 Cr | ₹210.05 Cr | ₹276.61 Cr |
| Other Income | ₹4.19 Cr | ₹9.57 Cr | ₹23.9 Lakh | ₹1.26 Cr | ₹6.07 Cr | ₹6.53 Cr |
| Total Income | ₹107.79 Cr | ₹146.37 Cr | ₹177.06 Cr | ₹219.63 Cr | ₹216.12 Cr | ₹283.14 Cr |
| Cost of Materials Consumed | ₹60.12 Cr | ₹85.39 Cr | ₹107.87 Cr | ₹142.92 Cr | ₹92.75 Cr | ₹155.17 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹1.79 Cr | -₹18.07 Cr | ₹160.76 Cr | ₹48.48 Lakh | ₹4.31 Cr | -₹4.87 Cr |
| Employee Benefit Expense | ₹23.04 Cr | ₹29.45 Cr | ₹28.7 Cr | ₹31.67 Cr | ₹32.36 Cr | ₹31.87 Cr |
| Finance Costs | ₹2.53 Cr | ₹1.9 Cr | ₹35.28 Cr | ₹39.53 Cr | ₹41.49 Cr | ₹43 Cr |
| Depreciation & Amortisation | - | ₹18.41 Cr | ₹106.91 Cr | ₹17.45 Cr | ₹15.8 Cr | ₹16.57 Cr |
| Other Expenses | ₹36.17 Cr | ₹73.67 Cr | ₹67.67 Cr | ₹52.51 Cr | ₹58.83 Cr | ₹62.15 Cr |
| Total Expenses | ₹138.71 Cr | ₹190.75 Cr | ₹507.19 Cr | ₹284.56 Cr | ₹245.54 Cr | ₹303.88 Cr |
| Profit Before Exceptional Items & Tax | - | -₹44.38 Cr | -₹330.13 Cr | -₹64.93 Cr | -₹29.42 Cr | -₹20.74 Cr |
| Exceptional Items | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹30.92 Cr | -₹44.38 Cr | -₹330.13 Cr | -₹64.93 Cr | -₹29.42 Cr | -₹20.74 Cr |
| Total Tax Expense | ₹0 | ₹0 | -₹2.12 Cr | ₹2.82 Cr | -₹23.44 Lakh | -₹1.57 Cr |
| Net Profit | -₹30.92 Cr | -₹44.38 Cr | -₹328.01 Cr | -₹67.75 Cr | -₹29.19 Cr | -₹19.17 Cr |
| Other Comprehensive Income | - | ₹47.6 Lakh | ₹4.05 Cr | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | - | -₹43.91 Cr | -₹323.96 Cr | -₹67.75 Cr | -₹29.19 Cr | -₹19.17 Cr |
| EBITDA (computed) | - | -₹24.07 Cr | -₹187.94 Cr | -₹7.96 Cr | ₹27.86 Cr | ₹38.83 Cr |
| Basic EPS | - | ₹-5.35 | ₹-39.56 | ₹-8.17 | ₹-3.55 | ₹-2.31 |
| Diluted EPS | - | ₹-5.20 | ₹-38.40 | ₹-7.93 | ₹-3.44 | ₹-2.24 |
| Metrics | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total Assets | ₹638.95 Cr | ₹681.47 Cr | ₹792.26 Cr |
| Non-current Assets | ₹391.18 Cr | ₹405.75 Cr | ₹524.66 Cr |
| Current Assets | ₹247.78 Cr | ₹275.72 Cr | ₹267.59 Cr |
| Property, Plant & Equipment | ₹247.87 Cr | ₹257.61 Cr | ₹272.23 Cr |
| Inventories | ₹56.5 Cr | ₹62.77 Cr | ₹78.31 Cr |
| Trade Receivables | - | ₹59.54 Cr | ₹52.96 Cr |
| Cash & Equivalents | ₹28.9 Lakh | ₹1.14 Cr | ₹3.35 Cr |
| Equity (Net Worth) | - | ₹89.41 Cr | ₹133.32 Cr |
| Equity Share Capital | - | ₹16.58 Cr | ₹16.58 Cr |
| Borrowings (Non-current) | - | ₹63.32 Cr | ₹61.98 Cr |
| Borrowings (Current) | - | ₹312.16 Cr | ₹314.66 Cr |
| Total Debt (computed) | - | ₹375.47 Cr | ₹376.64 Cr |
| Current Liabilities | ₹393.21 Cr | ₹391.17 Cr | ₹415.83 Cr |
| Total Liabilities | - | ₹592.06 Cr | ₹658.94 Cr |
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | ₹5.74 Cr | -₹96.52 Cr | ₹14.5 Cr | ₹25.31 Cr |
| Investing Cash Flow | -₹4.06 Cr | ₹99.83 Cr | -₹1.6 Cr | -₹11.34 Cr |
| Financing Cash Flow | -₹2.53 Cr | -₹5.5 Cr | -₹16.33 Cr | -₹13.21 Cr |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹11.34 Cr |
| Free Cash Flow (computed) | ₹5.74 Cr | -₹96.52 Cr | ₹14.5 Cr | ₹13.97 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | -₹3.87 Cr |
| Net Change in Cash | -₹85.5 Lakh | -₹2.2 Cr | -₹3.43 Cr | ₹6.77 Cr |
| Metrics | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 | Q4 FY23 | Q3 FY23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹18.66 Cr | ₹17.94 Cr | ₹22.58 Cr | ₹34.23 Cr | ₹22.16 Cr | ₹24.64 Cr | ₹36.39 Cr | ₹37.14 Cr | ₹30.28 Cr | ₹33 Cr | ₹39.72 Cr | ₹50.56 Cr |
| Other Income | ₹16 Lakh | ₹36 Lakh | ₹4.15 Cr | ₹30,000 | ₹2.7 Lakh | ₹30,000 | ₹7.37 Cr | ₹3.7 Lakh | ₹2.16 Cr | ₹80,000 | ₹0 | ₹90,000 |
| Total Income | ₹18.82 Cr | ₹18.3 Cr | ₹26.73 Cr | ₹34.24 Cr | ₹22.19 Cr | ₹24.64 Cr | ₹43.76 Cr | ₹37.17 Cr | ₹32.44 Cr | ₹33.01 Cr | ₹39.72 Cr | ₹50.57 Cr |
| Cost of Materials Consumed | ₹6.01 Cr | ₹10.11 Cr | ₹12.34 Cr | ₹15.81 Cr | ₹15.02 Cr | ₹16.95 Cr | ₹30.92 Cr | ₹19.76 Cr | ₹16.99 Cr | ₹17.72 Cr | ₹22.75 Cr | ₹34.12 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹3.82 Cr | -₹97.5 Lakh | -₹82.5 Lakh | ₹5.61 Cr | -₹4.11 Cr | -₹2.46 Cr | -₹18.6 Cr | ₹30.5 Lakh | ₹37.6 Lakh | -₹15.5 Lakh | ₹159.25 Cr | ₹1.45 Cr |
| Employee Benefit Expense | ₹4.58 Cr | ₹4.51 Cr | ₹7.07 Cr | ₹5.93 Cr | ₹5.09 Cr | ₹4.95 Cr | ₹5.69 Cr | ₹8.59 Cr | ₹8.59 Cr | ₹6.57 Cr | ₹7.92 Cr | ₹8.44 Cr |
| Finance Costs | ₹1.6 Cr | ₹52.2 Lakh | ₹1.48 Cr | ₹43.1 Lakh | ₹37.3 Lakh | ₹25.1 Lakh | -₹33.69 Cr | ₹13.16 Cr | ₹11.82 Cr | ₹10.61 Cr | ₹8.07 Cr | ₹9.16 Cr |
| Depreciation & Amortisation | ₹4.68 Cr | ₹4.8 Cr | - | ₹6.37 Cr | ₹3.86 Cr | ₹3.79 Cr | ₹4.96 Cr | ₹4.49 Cr | ₹4.49 Cr | ₹4.49 Cr | ₹95.07 Cr | ₹3.8 Cr |
| Other Expenses | ₹5.57 Cr | ₹4.83 Cr | ₹5.89 Cr | ₹7.07 Cr | ₹6.94 Cr | ₹9.21 Cr | ₹47.2 Cr | ₹7.59 Cr | ₹9.73 Cr | ₹9.16 Cr | ₹13.58 Cr | ₹12.71 Cr |
| Total Expenses | ₹26.26 Cr | ₹23.8 Cr | ₹30.56 Cr | ₹41.21 Cr | ₹27.18 Cr | ₹32.69 Cr | ₹36.47 Cr | ₹53.89 Cr | ₹52 Cr | ₹48.39 Cr | ₹306.63 Cr | ₹69.69 Cr |
| Profit Before Exceptional Items & Tax | -₹7.45 Cr | -₹5.5 Cr | - | -₹6.97 Cr | -₹4.99 Cr | -₹8.06 Cr | ₹7.28 Cr | -₹16.72 Cr | -₹19.56 Cr | -₹15.38 Cr | -₹266.91 Cr | -₹19.12 Cr |
| Exceptional Items | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹7.45 Cr | -₹5.5 Cr | -₹3.84 Cr | -₹6.97 Cr | -₹4.99 Cr | -₹8.06 Cr | ₹7.28 Cr | -₹16.72 Cr | -₹19.56 Cr | -₹15.38 Cr | -₹266.91 Cr | -₹19.12 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1.77 Cr | -₹55.4 Lakh | ₹0 | ₹0 | -₹2.07 Cr | ₹0 |
| Net Profit | -₹7.45 Cr | -₹5.5 Cr | -₹3.84 Cr | -₹6.97 Cr | -₹4.99 Cr | -₹8.06 Cr | ₹5.51 Cr | -₹16.17 Cr | -₹19.56 Cr | -₹15.38 Cr | -₹264.85 Cr | -₹19.12 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹47.6 Lakh | ₹0 | ₹0 | ₹0 | ₹4.05 Cr | ₹0 |
| Total Comprehensive Income | -₹7.45 Cr | -₹5.5 Cr | - | -₹6.97 Cr | -₹4.99 Cr | -₹8.06 Cr | ₹5.99 Cr | -₹16.17 Cr | -₹19.56 Cr | -₹15.38 Cr | -₹260.8 Cr | -₹19.12 Cr |
| EBITDA (computed) | -₹1.16 Cr | -₹17.7 Lakh | - | -₹17.6 Lakh | -₹75.8 Lakh | -₹4.01 Cr | -₹21.45 Cr | ₹92 Lakh | -₹3.25 Cr | -₹28.3 Lakh | -₹163.77 Cr | -₹6.16 Cr |
| Basic EPS | ₹-0.90 | ₹-0.66 | - | ₹-0.84 | ₹-0.60 | ₹-0.97 | ₹0.67 | ₹-1.25 | ₹-2.36 | ₹1.86 | ₹-31.94 | ₹-0.22 |
| Diluted EPS | ₹-0.87 | ₹-0.64 | - | ₹-0.82 | ₹-0.58 | ₹-0.94 | ₹0.65 | ₹-1.22 | ₹-2.29 | ₹1.80 | ₹-31.01 | ₹-0.23 |
| Segment · Q2 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| sale | ₹0 | ₹0 | ₹0 | ₹0 |
| Segment · FY 2024 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharma Business | ₹130.9 Cr | -₹26.02 Cr | - | - |
| Speciality Chemicals Business | ₹5.9 Cr | -₹26.03 Cr | - | - |
Shareholding Pattern of Vivimed Labs (Alathur) Private Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 7.57%, foreign institutional investors hold 1.64%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 90.67% of Vivimed Labs (Alathur) Private Limited. The company had 47,492 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 7.57% | 7.77% | 7.77% | 7.77% | 20.94% | 20.94% |
| Public | 92.43% | 92.23% | 92.23% | 92.23% | 79.06% | 79.06% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 7.57% | 20.94% | 20.94% | 20.94% | 21.98% | 28.57% | 32.79% | 34.39% | 36.64% | 36.48% | 36.82% |
| Public | 92.43% | 79.06% | 79.06% | 79.06% | 78.02% | 71.43% | 67.21% | 65.61% | 63.36% | 63.52% | 63.18% |
| Promoter change (YoY, %pts) | -13.37 | +0.00 | +0.00 | -1.04 | -6.59 | -4.22 | -1.60 | -2.25 | +0.16 | -0.34 | - |
Board & Governance of Vivimed Labs (Alathur) Private Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Vivimed Labs (Alathur) Private Limited has 6 directors - 3 independent and 3 executive. The board is chaired by Manohar Rao Varalwar.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Santosh Varalwar | Executive Director · MD | 1989-11-09 | 1 |
| Manohar Rao Varalwar | Executive Director · Chairperson | 1994-11-10 | 1 |
| Sandeep Varalwar | Executive Director | 2008-01-23 | 1 |
| Aparna Bidarkar | Non-Executive - Independent Director | 2022-02-14 | 1 |
| Jarugula Siva Prasad | Non-Executive - Independent Director | 2024-12-11 | 1 |
| Subbarathnamma Palepu | Non-Executive - Independent Director | 2024-12-11 | 3 |
| Committee | Members |
|---|---|
| Audit Committee | Jarugula Siva Prasad (Chairperson), Sandeep Varalwar, Aparna Bidarkar, Subbarathnamma Palepu |
| Nomination and remuneration committee | Aparna Bidarkar (Chairperson), Jarugula Siva Prasad, Subbarathnamma Palepu |
| Stakeholders Relationship Committee | Subbarathnamma Palepu (Chairperson), Santosh Varalwar, Manohar Rao Varalwar, Jarugula Siva Prasad |
| Corporate Social Responsibility Committee | Santosh Varalwar, Manohar Rao Varalwar, Subbarathnamma Palepu, Jarugula Siva Prasad |
Charges & Borrowings of Vivimed Labs (Alathur) Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Mar 2010 | Tamilnadu Industrial Investment Corporation Limited | ₹20 Cr | Satisfied |
| 15 Nov 2007 | Hdfc Bank Limited | ₹12.5 Cr | Satisfied |
| 23 Oct 2007 | Idbi Bank | ₹21 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Vivimed Labs (Alathur) Private Limited
View historical data on people associated with Vivimed Labs (Alathur) Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Vivimed Labs (Alathur) Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Vivimed Labs (Alathur) Private Limited
GSTIN & GST Filing Data of Vivimed Labs (Alathur) Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Vivimed Labs (Alathur) Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Vivimed Labs (Alathur) Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Vivimed Labs (Alathur) Private Limited
MSME Payment Delays by Vivimed Labs (Alathur) Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Vivimed Labs (Alathur) Private Limited
Subsidiaries & Group Companies of Vivimed Labs (Alathur) Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Vivimed Labs (Alathur) Private Limited with ownership details.
MCA Filings & Documents of Vivimed Labs (Alathur) Private Limited
MCA Filings & Documents of Vivimed Labs (Alathur) Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Vivimed Labs (Alathur) Private Limited
Recent News on Vivimed Labs (Alathur) Private Limited
Frequently Asked Questions about Vivimed Labs (Alathur) Private Limited
Vivimed Labs (Alathur) Private Limited has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.
Vivimed Labs (Alathur) Private Limited is a amalgamated private limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 23 November 2006 and is registered under CIN U24219MH2006PTC165760. The company was amalgamated as per MCA records and no longer exists as a legal entity.
Vivimed Labs (Alathur) Private Limited was incorporated on 23 November 2006. Registered with ROC Mumbai.
The current directors of Vivimed Labs (Alathur) Private Limited are:
The CIN (Corporate Identification Number) of Vivimed Labs (Alathur) Private Limited is U24219MH2006PTC165760. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The primary industry of Vivimed Labs (Alathur) Private Limited is pharma. The company specifically operates in drug formulation and development.